Anti-TNF alpha medications and neuropathy.

Détails

ID Serval
serval:BIB_DA553F1DD0E2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Anti-TNF alpha medications and neuropathy.
Périodique
Journal of the Peripheral Nervous System : Jpns
Auteur(s)
Tsouni P., Bill O., Truffert A., Liaudat C., Ochsner F., Steck A.J., Kuntzer T.
ISSN
1529-8027 (Electronic)
ISSN-L
1085-9489
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
20
Numéro
4
Pages
397-402
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8 months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents.
Mots-clé
Adalimumab/adverse effects, Adalimumab/therapeutic use, Adult, Aged, Autoimmune Diseases/drug therapy, Electrodiagnosis, Etanercept/adverse effects, Etanercept/therapeutic use, Female, Humans, Infliximab/adverse effects, Infliximab/therapeutic use, Male, Middle Aged, Neural Conduction/physiology, Peripheral Nervous System Diseases/chemically induced, Peripheral Nervous System Diseases/diagnosis, Rheumatic Diseases/drug therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Création de la notice
19/02/2016 19:47
Dernière modification de la notice
03/03/2018 21:54
Données d'usage